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Dementia is one of the most disabling conditions. Alzheimer’s disease and vascular dementia (VaD) are the most frequent
causes. Subcortical VaD is consequent to deep-brain small vessel disease (SVD) and is the most frequent form of VaD. Its
pathological hallmarks are ischemic white matter changes and lacunar infarcts. Degenerative and vascular changes often coexist,
but mechanisms of interaction are incompletely understood. The term mild cognitive impairment defines a transitional state
between normal ageing and dementia. Pre-dementia stages of VaD are also acknowledged (vascular mild cognitive impairment,
VMCI). Progression relates mostly to the subcortical VaD type, but determinants of such transition are unknown. Variability
of phenotypic expression is not fully explained by severity grade of lesions, as depicted by conventional MRI that is not
sensitive to microstructural and metabolic alterations. Advanced neuroimaging techniques seem able to achieve this. Beside
hypoperfusion, blood-brain-barrier dysfunction has been also demonstrated in subcortical VaD. The aim of the Vascular Mild
Cognitive Impairment Tuscany Study is to expand knowledge about determinants of transition from mild cognitive impairment
to dementia in patients with cerebral SVD. This paper summarizes the main aims and methodological aspects of this multicenter,
ongoing, observational study enrolling patients aﬀected by VMCI with SVD.
1. Introduction
Dementia is one of the most disabling conditions aﬀecting
older people. The most frequent cause is Alzheimer’s disease
(AD) which is attributed to brain cortex degeneration.
In Italy one-third of dementia cases are due to vascular
dementia (VaD), a term that encompasses a few subtypes,
among which subcortical VaD consequent to deep brain
small vessel disease (SVD) is the most frequent [1]. Its
pathological hallmarks are ischemic white matter changes,
caused by hypoperfusion and lacunar infarcts [2]. These
changes can progress over time silently, a profile similar to
that occurring in AD. In the old brain degenerative and
vascular changes may often coexist and possibly interact.
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However, the exact mechanisms of such interaction are still
incompletely understood [3]. Data suggest that vascular
factors play a role also in AD [4]. How they contribute to
both dementia types is a relevant issue, as they can be treated,
favorably altering the progression of cognitive decline. In
the neurovascular unit, vessels and cells, including neurons,
closely interact, pointing to endothelial dysfunction as a
key element for explaining neuronal damage associated with
both subcortical VaD and AD.
The term mild cognitive impairment (MCI) defines
a transitional state between normal ageing and dementia
and is thought to anticipate dementia [5]. Subjects with
MCI, compared to those without, progress to AD at a rate
ten times greater [6]. Pre-dementia stages of VaD are also
acknowledged: this condition is referred to as vascular mild
cognitive impairment (VMCI) [7]. In the Canadian Health
and Aging Study 46% of patients with VMCI developed
dementia after 5 years [8]. Progression relates mostly to the
subcortical VaD type. The determinants of this transition are
not fully elucidated: it is not clear whether it is mainly driven
by vascular, degenerative processes, or by their interaction.
The increase in white matter changes and the accumulation
of small infarcts proved to be associated with the cognitive
decline [7]. Data show that brain atrophy is also associated
with cognitive deterioration [9].
Phenotypic expression of subcortical VaD is variable.
Variability is not fully explained by severity grade of
lesions, as depicted by conventional MRI. This seems not
enough sensitive in diﬀerentiating axonal loss and glia
damage from intact structures. Furthermore, it does not
provide pathophysiological details about changes ongoing
in both parenchyma and vessels. Advanced techniques such
as magnetization transfer, diﬀusion, and spectroscopy seem
able to yield more in-depth information about the extent of
tissue damage, its microstructural nature, and the underlying
metabolic alterations [10]. Beside hypoperfusion, blood
brain-barrier dysfunction has been also demonstrated in
subcortical VaD [11, 12]. Since many factors associated
with subcortical VaD are treatable, it seems of the utmost
importance to expand the knowledge about determinants
and mechanisms underlying the transition from VMCI to
dementia. Estimating the relative weight of the predictive
eﬀect for each significant determinant (among the clinical,
functional, imaging, and biological potential markers) of
the transition may allow to evaluate the risk of dementia
and to describe the risk-factor profile in individual patients
with subcortical MCI, thus favoring tailored and appropriate
preventive strategies.
During the last 10 years many clinical and functional out-
comes in elderly patients with subcortical vascular changes
have been investigated through a European multicenter
collaboration called LADIS (leukoaraiosis and disability)
Study [13]. The LADIS study, supported by the European
Union, has been carried out in 11 European high-quality
centers, coordinated by the Department of Neurological
and Psychiatric Sciences of the University of Florence.
Concerning the main study outcome, that is, transition to
disability, results have shown that the risk of transition or
death was more than twofold higher in patients with severe
white matter changes compared to those with mild degrees
[14]. Some vascular risk factors also predicted the transition.
A review summarizing the LADIS main results has recently
been published [15]. White matter changes also had an eﬀect
on cognitive decline and dementia. Cross-sectional baseline
data analysis indicated that white matter changes and medial
temporal lobe atrophy were independently associated with
cognitive impairment [9]. At multivariable analysis, risk
factors and the conventional MRI features were able to
explain only part of the prediction of either disability or
dementia [16]. It was thus decided to perform a new
study, the VMCI-Tuscany Study, with the main aims of:
(1) estimating the net and multivariable eﬀect in predicting
the transition from VMCI to dementia studying a large set
of both conventional and nonconventional clinical, neuro-
imaging, and biological markers of SVD; (2) assessing the
vascular and degenerative components in the determination
of such transition, that is, their relative contribution and
their possible interaction; (3) generating from the results of
the multivariable predictive model a diagnostic algorithm
able to determine the risk of transition in individual patients
with VMCI with SVD.
2. Methods
The VMCI-Tuscany Study foresees the collaboration of the
three university hospital centers in Tuscany: Florence, Pisa,
and Siena (Department of Neurological and Psychiatric
Sciences, University of Florence, Unit of Neurology and
Neurophysiopathology, Azienda Ospedaliero-Universitaria
Pisana, and Unit of Neurology and Neurometabolic Diseases,
Azienda Universitaria Ospedaliera Senese) where the enrol-
ment and assessment of patients with VMCI and SVD is
actually ongoing. In order to reach the prespecified number
of patients in the foreseen time period, the project has been
promoted at all the regional, both neurological and geriatric,
hospital units (Figure 2).
2.1. Inclusion Criteria. To be included, patients have to be
classified as aﬀected by VMCI with SVD according to the
following criteria: (1) MCI defined according to Winblad
et al. criteria [17], and (2) evidence on MRI of subcortical
vascular lesions of moderate to severe degrees of white matter
changes (WMC), according to the modified version of the
Fazekas scale [13] (Figure 1). Each patient gives a written
informed consent, and the study has been approved by local
ethical committees.
2.2. Exclusion Criteria. Exclusion criteria are inability or
refusal to undergo cerebral MRI, and inability to give an
informed consent.
Sample size was estimated based on data about transition
to dementia obtained in the LADIS Study. In the LADIS sam-
ple, patients with baseline mild cognitive impairment and
moderate to severe WMC, had an annual rate of transition
to dementia of 10%. Three hundred patients were considered
the minimal number necessary to carry out multivariate
analyses of potential predictors of transition to dementia.
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Figure 1: Cerebral white matter changes: examples of mild, moderate, and severe groups according to the modified Fazekas’ scale. Only
patients with moderate or severe degrees were included in the study.
2.2.1. Baseline Assessment. According to the study protocol,
each patient enrolled undergoes an extensive clinical assess-
ment and an MRI examination and permits the collection of
blood samples for the determination of plasma biomarkers.
Tables 1, 2, and 3 summarize main objectives and instru-
ments for the clinical, neuroimaging, and laboratory assess-
ments, respectively.
2.3. Clinical Assessment (Table 1). Social background and
medical history are collected according to a structured and
comprehensive questionnaire administered to the patient
by trained personnel. This includes information on demo-
graphic characteristics, education (expressed as years of
schooling), occupational status, longest job in life, marital
status, living conditions, lifestyle habits (alcohol consump-
tion, smoking, physical activity), and vascular risk factors.
Furthermore, patients are specifically asked if they experi-
ence gait, memory, visual, or hearing problems, or bladder
disturbances. Several other age-related comorbidities are
assessed with the aim of controlling for their eﬀect on the
main study outcome. All possible medical information and
records were collected and reviewed during the interview
in order to reach or confirm the diagnosis of the diseases
under investigation. If needed, contact with the family
doctor can also be undertaken. All conditions were defined
according to the currently most widely accepted criteria,
selected after a systematic literature search. The whole set of
criteria is reported in a specifically developed manual and
distributed to all participating centers. Information is also
collected about thyroid diseases, head injuries, falls in the
last year. Data on family history of migraine, epilepsy, psy-
chiatric disturbances, stroke, dementia, venous thrombosis,
diabetes mellitus, hypertension, and hyperlipidemias are also
recorded. Currently used drugs are registered in a structured
way.
Blood pressure, weight, and height measurements are
recorded, and a standard neurological examination is per-
formed. The absence or presence of the following neurologi-
cal examination abnormalities is assessed: upper motor neu-
ron signs, extrapyramidal signs, cerebellar signs, cortical
signs (language deficits and/or visual field abnormalities),
pseudobulbar signs (hypophonia and/or dysphagia and/or
dysarthria), and primitive reflexes (one or more of the fol-
lowing: grasp reflex, palmomental reflex, forced laughing and
crying, snout reflex, glabellar tapping). Speed of finger taps
(patient taps thumb with index finger in rapid succession
4 International Journal of Alzheimer’s Disease
Vascular mild cognitive 
impairment in Tuscany
VMCI-Tuscany
http://www.vmci-tuscany.it/
Figure 2: List of participating centers and personnel in the VMCI-
Tuscany. University of Florence: (Coordinating Center): Domenico
Inzitari (study coordinator), Rosanna Abbate, Manuela Bandinelli,
Maria Boddi, Francesca Cesari, Laura Ciolli, Mirella Coppo,
Alessandra Del Bene, Stefano Diciotti, Andrea Ginestroni, Betti
Giusti, Anna Maria Gori, Mario Mascalchi, Serena Nannucci,
Leonardo Pantoni, Marco Pasi, Francesca Pescini, Anna Poggesi,
Giovanni Pracucci, Emilia Salvadori, Raﬀaella Valenti. University
of Pisa: Luigi Murri, Ubaldo Bonucelli, Paolo Cecchi, Alberto
Chiti, Mirco Cosottini, Giovanni Orlandi, Cristina Pagni, Gabriele
Siciliano, Gloria Tognoni. University of Siena: Antonio Federico,
Nicola De Stefano, Maria Teresa Dotti, Patrizia Formichi, Claudia
Gambetti, Antonio Giorgio, Francesca Rossi, Laura Stromillo, Enza
Zicari. Tuscany region: Arezzo (Paolo Zolo, Alessandro Tiezzi);
Empoli (Elisabetta Bertini, Stefania Brotini, Leonello Guidi, Maria
Lombardi, Stefania Mugnai, Antonella Notarelli); Florence (Laura
Bracco, Massimo Cadelo, Renzo Cisbani, Luciano Gabbani, Guido
Gori, Lorella Lambertucci, Luca Massacesi, Enrico Mossello, Marco
Paganini, Maristella Piccininni, Francesco Pinto, Claudia Pozzi,
Sandro Sorbi, Gaetano Zaccara); Grosseto (Tiziano Borgogni, Mario
Mancuso, Roberto Marconi); Lucca (Monica Mazzoni, Marco
Vista); Livorno (Giuseppe Meucci, Giovanna Bellini); Massa Carrara
(Luciano Gabrielli); Pisa (Cristina Frittelli, Renato Galli, Gianna
Gambaccini); Pistoia (Stefano Bartolini, Carlo Biagini, Veronica
Caleri, Paola Vanni); Prato (Donatella Calvani, Carla Giorgi, Stefano
Magnolfi, Pasquale Palumbo, Carlo Valente); Siena (Alessandro
Rossi, Rossana Tassi, Stefania Boschi); Viareggio (Filippo Baldacci;
Ubaldo Bonuccelli).
with widest amplitude possible) is assessed for each hand
separately and scored as normal, mild slowing, moderately
impaired, severely impaired, or barely able to perform the
task (range 1 to 5). Gait and stance are coded as normal
or abnormal. Concerning motor function, a standardized
assessment is performed by means of the short physical
performance battery (SPPB), and two additional simple
measures of gait and balance, that is, gait velocity and single
leg stance time, as already used in the LADIS study [18–
20, 34].
Each patient is assessed by means of an extensive
neuropsychological evaluation according to the specifically
Table 1: Instruments for patients’ assessment in the VMCI-Tuscany
study protocol.
Instruments/methods References
Clinical assessment
Social background and
medical history according to
structured protocol
—
Standard cardiovascular and
neurological examination
according to structured
protocol
—
Motor performances
Short physical performance
battery (SPPB)
[18]
Single leg stance [19]
Gait velocity [20]
Cognitive
performances
Mini mental state
examination (MMSE)
[21]
Montreal cognitive assessment
battery (MoCA)
[22]
Rey auditory-verbal learning
test
[23]
Trail making test (A and B) [24]
Color word stroop test [25]
Symbol digit modalities test [26]
Visual search [27]
Phonemic and semantic
fluency
[28]
Rey-Osterrieth complex figure [29]
Short story recall test [30]
Mood
Geriatric depression scale
(GDS-15)
[31]
Global functioning
Activities of daily living (ADL)
scale
Instrumental activities of daily
living (IADL) scale
[32]
[33]
developed test battery. How the neuropsychological test
battery was developed and the way it allows automation and
standardization of the scoring procedures will be reported in
a separate paper. In brief, the cognitive functions assessed
include global mental functioning, orientation, memory,
attention, executive functions, language, speed and motor
control. The tests used are reported in Table 1 [21–30]. The
geriatric depression scale (GDS) is used for the assessment
of mood [31]. Functional status is measured by means of the
activities of daily living scale and the instrumental activities
of daily living scale [32, 33]: these 2 scales are addressed to
the patient’s caregiver, given the longitudinal design of the
study and the possible transition to dementia of the patient.
In order to increase consistency and homogeneity in
the assessments, all investigators participated to at least one
training session and were provided with a specifically devel-
oped handbook with guidelines for the correct use of criteria
and tools.
2.4. MRI Examination (Table 2). Patients are examined on
clinical 1.5 T system (Intera, Philips Medical System, Best,
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Table 2: MRI protocol in the VMCI-Tuscany Study.
Sequences
(i) Axial high-resolution contiguous 3D T1-weighted
images with isotropic voxels (MPRAGE sequence)
(ii) Axial T2-weighted images (FLAIR sequence)
(iii) Diﬀusion tensor imaging (DTI)
(iv) Functional MRI (motor or cognitive tasks)
(v) T2∗-sensitive echo-planar imaging (EPI) sequence
Table 3: Plasma biomarkers under investigation in the VMCI-
Tuscany Study.
Markers of endothelial
function
von Willebrand factor, tissue factor,
tissue factor pathway inhibitor,
intercellular adhesion molecule-1 and
count of the number of circulating
endothelial progenitor cells by
cytofluorimetric method using
monoclonal antibodies anti-staminal
cells markers (CD34 and AC133) and
anti-endothelial cell markers
(VEGFR2)
Polymorphisms associated
with cerebral small vessels
disease
Genes coding metalloproteases and
their inhibitors, renin-angiotensin
system components, genes coding
endothelial nitroxide synthase
Pro- and anti-inflammatory
molecules
interleukin-6, interleukin-1-RA,
interleukin-8, interleukin-10,
interleukin-18, and C-reactive protein
The Netherlands) with 33 mT/m gradients capability and a
head coil with SENSE technology. After scout, the examina-
tion protocol includes a sagittal T1 weighted 3D T1-weighted
turbo gradient echo sequence (repetition time (TR) = 8.1 ms,
echo time (TE) = 3.7 ms, flip angle = 8◦, inversion time (TI)
= 764 ms, field of view (FOV) = 256 mm, matrix size = 256
× 256, 160 contiguous slices, slice thickness = 1 mm) axial
FLAIR sequence (TR = 11000 ms, TE = 140 ms, inversion
time (TI) = 2800 ms, FOV = 230 mm, matrix size = 320 ×
216, contiguous slices, slice thickness = 5 mm), and axial
single-shot echo planar imaging sequence (TR = 9394 ms, TE
= 89 ms, FOV = 256 mm, matrix size = 128 × 128, 50 slices,
slice thickness = 3 mm, no gap, NEX = 3; diﬀusion sensitizing
gradients applied along 15 non-collinear directions using
b value of 0 (b0 image) and 1000 s/mm2) for DTI. A T2∗
weighted echo planar imaging sequence is used for the
functional MRI. Details of such experiments are reported
elsewhere.
2.5. Laboratory Analyses (Table 3). Tests for plasma biomark-
ers will be performed centrally, in Florence, Center for
Thrombosis, after the collection of blood samples of all
recruited patients will be completed. Laboratory investiga-
tions will then include the determination of those plasma
biomarkers which, according to literature review, have been
found to be associated with white matter changes. At the
moment, the possible set of plasma biomarkers is composed
of markers of endothelial function, polymorphisms associ-
ated with cerebral small vessels disease, and pro- and anti-
inflammatory molecules (see Table 3 for details).
2.5.1. Follow-Up Assessment. The longitudinal design of the
VMCI-Tuscany study encompass a clinical, functional, and
neuropsychological assessment, according to the main study
protocol already used at baseline, performed yearly after
enrollment, for two years consecutively. The MRI assessment
is performed at baseline and then repeated after two years,
at the end of the study. This second MRI is planned with
the aim of evaluating possible progression of both vascular
and nonvascular lesions and of studying this progression in
correlation with the evolution of clinical/functional deficits
and the onset of dementia.
2.6. Outcome Measures. The main study outcomes will be
the diagnosis of dementia and the occurrence of cognitive
decline. Dementia diagnosis will be made according to DSM-
IV criteria [35]. The diagnosis of vascular dementia will be
made according to specific criteria [36]; the diagnosis of the
main subtypes of vascular dementia will be performed for
consensus according to clinical and neuroimaging charac-
teristics. AD diagnosis will be performed according to the
clinical research criteria [37]. Staging of dementia severity
will be performed according to clinical dementia rating scale
[38]. Cognitive decline will be evaluated as a decrease in the
compound scores for each cognitive domain.
2.7. Data Management. Data collected in each center is
entered into an electronic database on a specifically devel-
oped website (http://www.vmci-tuscany.it/). This allows the
systematic and rapid control of completeness and online
quality of data in real time.
3. Results
The study began on October 15, 2010. The first four months
of the study have been dedicated to the preparation of
all the study instruments and training of the participating
personnel. During this first phase, the definitive project
protocol has been established and shared by all the inves-
tigators, and the homogeneity of the clinical-functional
and MRI sequences parameters have been tested across
the three centres and investigators. The dedicated website
for communications, storage of study instruments, and
database for data collection has been created and is operative
(http://www.vmci-tuscany.it/).
On February 15, 2011, the enrollment of patients was
started. Up to now, eight months after the beginning of
the study, 76 patients with moderate to severe WMC have
been evaluated according to the entire study protocol. Mean
age is 75.2 ± 7.4, 47 (62%) are males, and mean education,
expressed as years of schooling, is 7.5 ± 3.9. Mean MMSE
score is 26.6± 2.7, and mean MoCA score is 19.6± 5.0.
The end of the enrollment is scheduled for the end of
2012.
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4. Discussion
The VMCI-Tuscany Study is one of the first longitudinal
studies assessing determinants of the transition from a stage
of mild cognitive impairment to dementia. For the first time
the study will focus on a particular form of cerebrovascular
disease as a cause of cognitive decline, that is, cerebral small
vessel disease. Up to now, the study protocol showed a
good feasibility and applicability in patients with VMCI and
SVD. The first aim of the study is to investigate a large set
clinical, neuroimaging, and biological markers of cerebral
small vessel disease in predicting the transition from a stage
of mild cognitive impairment to dementia. Secondly, the
study will permit the assessment of the relative contribution,
and possible interaction, of vascular and degenerative com-
ponents in the determination of such transition. Last, but
not least, final results of the multivariable predictive model
will enable the generation a diagnostic algorithm able to
determine the risk of transition to dementia in individual
patients with VMCI and SVD.
Data from the literature show that the clinical and
functional status in subjects with the same grade of WMC
may be variable, suggesting the presence of “hidden” factors
in determining the clinical picture [39]. Despite the known
role of SVD in the determination of cognitive impairment,
its net weight remains to be appreciated. For example it is
known that some patients with similar visible SVD burden
have diﬀerent clinical outcomes, hinting at the presence
of additional, uncovered aspects that may contribute to
this transition. This uncovered aspect may relate to the
same pathogenic process (SVD) but be undetected under
routine assessment (e.g., conventional MRI) and instead
be detected by new techniques [39]. The morphological
alterations identified on conventional neuroimaging do not
appear suﬃcient to explain the clinical-functional phenotype
which is frequently variable for typology and severity also in
presence of overlapping neuroimaging findings. A number
of studies have investigated the association between white
matter lesions extension, evaluated by means of visual
scales or volume measurements, and functional, cognitive
or motor disturbances, sometimes with inconsistent results.
A limitation of these studies is that the signal alterations
on conventional neuroimaging may be due to diﬀerent
degrees of parenchymal damage, from more or less severe
axonal loss to a glia damage with intact nervous fibers.
Conventional morphological neuroimaging is not able to
provide details about pathophysiological processes within
the cerebral parenchyma and vessels. Preliminary studies
using advanced neuroimaging techniques such as magneti-
zation transfer, diﬀusion, and spectroscopy have suggested
the possibility to acquire more in-depth information about
the microstructural tissue damage and underlying metabolic
alterations and the association with the cognitive perfor-
mances evaluating both white matter lesions revealed by
conventional neuroimaging and normal-appearing white
matter. However, such data have been obtained from small
cross-sectional studies and without considering the influence
of other frequently coexisting lesions such as lacunar infarcts
and cortical atrophy.
Knowledge about determinants of the transition to
dementia in patients with VMCI and SVD is essential to the
identification of potential preventive and therapeutic targets,
contributing to reduce the burden (on both the ethical
and economical grounds) of disability in the elderly. This
represents one of the greatest challenges for social and health
systems in our ageing society. Moreover, results from the
project may provide both health systems and professionals
with a validated instrument (i.e., a diagnostic algorithm
generated from the multivariable prediction models) for
estimating the risk of transition to dementia in individual
patients tailoring the appropriate preventive and therapeutic
strategy. Finally, the multivariable prediction of the risk of
cognitive decline and dementia in this population may rep-
resent an essential methodological background for designing
and sample-sizing-controlled clinical trials in the selective
clinical setting.
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